Literature DB >> 15511627

Significantly increased fractions of transformed to total alpha2-macroglobulin concentrations in plasma from patients with multiple sclerosis.

Poul Erik H Jensen1, Signe Humle Jørgensen, Pameli Datta, Per Soelberg Sørensen.   

Abstract

We examined the proteinase inhibitor alpha2-macroglobulin (alpha2M) in plasma from patients with multiple sclerosis (MS); a neurological disease of the central nervous system. The plasma concentrations of native and transformed alpha2M were measured in 90 patients with clinically definite MS, 73 with relapsing-remitting and 17 with secondary progressive MS, and 132 healthy individuals. Significantly lower concentrations of native alpha2M and significantly higher concentrations of transformed alpha2M were found in MS patients. A significant correlation between the concentrations of native and transformed alpha2M was found. The fraction of transformed to total alpha2M in the MS patients was 36% higher than in the healthy individuals. The results suggest an important involvement of alpha2M in regulation of increased proteolytic activity occurring in MS disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15511627     DOI: 10.1016/j.bbadis.2004.06.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  Identification of differentially expressed proteins in experimental autoimmune encephalomyelitis (EAE) by proteomic analysis of the spinal cord.

Authors:  Tong Liu; K Christian Donahue; Jun Hu; Michael P Kurnellas; Jennifer E Grant; Hong Li; Stella Elkabes
Journal:  J Proteome Res       Date:  2007-06-16       Impact factor: 4.466

2.  Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients.

Authors:  Nicolas Fissolo; Sabrina Haag; Katrien L de Graaf; Oliver Drews; Stefan Stevanovic; Hans Georg Rammensee; Robert Weissert
Journal:  Mol Cell Proteomics       Date:  2009-06-16       Impact factor: 5.911

3.  Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis.

Authors:  Kaushal S Gandhi; Fiona C McKay; Eve Diefenbach; Ben Crossett; Stephen D Schibeci; Robert N Heard; Graeme J Stewart; David R Booth; Jonathan W Arthur
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

4.  Finding disease candidate genes by liquid association.

Authors:  Ker-Chau Li; Aarno Palotie; Shinsheng Yuan; Denis Bronnikov; Daniel Chen; Xuelian Wei; Oi-Wa Choi; Janna Saarela; Leena Peltonen
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

5.  A Chronic Fatigue Syndrome - related proteome in human cerebrospinal fluid.

Authors:  James N Baraniuk; Begona Casado; Hilda Maibach; Daniel J Clauw; Lewis K Pannell; Sonja Hess S
Journal:  BMC Neurol       Date:  2005-12-01       Impact factor: 2.474

6.  Protease-activated alpha-2-macroglobulin can inhibit amyloid formation via two distinct mechanisms.

Authors:  Amy R Wyatt; Patrick Constantinescu; Heath Ecroyd; Christopher M Dobson; Mark R Wilson; Janet R Kumita; Justin J Yerbury
Journal:  FEBS Lett       Date:  2013-01-23       Impact factor: 4.124

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.